(Q53462532)

14 May 2018

title

Alzheimer disease: Lessons from immunotherapy for Alzheimer disease. (English)

1 reference

14 May 2018

0 references

1 reference

1

1 reference

14 May 2018

language of work or name

English

0 references

publication date

18 March 2014

1 reference

14 May 2018

published in

Nature Reviews Neurology

1 reference

14 May 2018

volume

10

1 reference

14 May 2018

issue

4

1 reference

14 May 2018

page(s)

188-189

1 reference

14 May 2018

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.44

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.44

A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.44

Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.44

Molecular basis for passive immunotherapy of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.44

Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.44

Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.44

Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.44

Deciphering the mechanism underlying late-onset Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.44

Immunotherapy for Alzheimer disease: the challenge of adverse effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.44

31 March 2020

Identifiers

DOI

10.1038/NRNEUROL.2014.44

1 reference

14 May 2018

1 reference

14 May 2018